Chinese Vaccine, Testing Reagent Companies Recorded Massive Profits Amid Lockdowns, Widespread Mandatory Testing

Vials of the CoronaVac vaccine, developed by China's Sinovac Biotech, are displayed in Bangkok, Thailand on Feb. 24, 2021. Lillian Suwanrumpha/AFP via Getty Images

The first quarter financial reports of COVID-19 vaccine and testing reagent manufacturers in China have shown huge profits compared to the same period last year.

China has experienced prolonged lockdowns and mandatory COVID-19 testing and vaccination nationwide since the outbreak of the pandemic. The Chinese regime’s top health body announced in April that China had administered a total of 3.27 billion doses of the COVID-19 vaccines as of March 31, 2022, at a cost of nearly $19 billion.